Quick Dispatch:
Your surmount-1 trial tirzepatide weight loss nondiabetic Tirzepatide for Obesity Treatment and Diabetes Prevention orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-1 trial tirzepatide weight loss nondiabetic Tirzepatide for Obesity Treatment and Diabetes Prevention ships.
Need Help?
Questions about surmount-1 trial tirzepatide weight loss nondiabetic Tirzepatide for Obesity Treatment and Diabetes Prevention, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-1 trial tirzepatide weight loss nondiabetic Tirzepatide for Obesity Treatment and Diabetes Prevention in your area.
SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients
26.33
SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes
26.47
SURMOUNT-1 Trial
24.89
SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants
27.78
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity
28.32
In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://bit.ly/4rBMZgh
26.54
For the first time, tirzepatide and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The
26.16
